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A general consensus acknowledges that drug consumption (including alcohol, tobacco,
and illicit drugs) constitutes the leading cause of preventable death worldwide. But
the global burden of drug abuse extends the mortality statistics. Indeed, the comorbid
long-term debilitating effects of the disease also significantly deteriorate the quality
of life of individuals suffering from addiction disorders. Despite the large body of
evidence delineating the cellular and molecular adaptations induced by chronic drug
consumption, the brain mechanisms responsible for drug craving and relapse remain
insufficiently understood, and even the most recent developments in the field have not
brought significant improvement in the management of drug dependence. Though, recent
preclinical evidence suggests that disrupting the hypocretin (orexin) system may serve
as an anticraving medication therapy. Here, we discuss how the hypocretins, which
orchestrate normal wakefulness, metabolic health and the execution of goal-oriented
behaviors, may be compromised and contribute to elicit compulsive drug seeking. We
propose an overview on the most recent studies demonstrating an important role for
the hypocretin neuropeptide system in the regulation of drug reward and the prevention
of drug relapse, and we question the relevance of disrupting the hypocretin system to
alleviate symptoms of drug addiction.
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THE GLOBAL BURDEN OF DRUG ADDICTION
“When it comes to kicking a drug habit, going through with-
drawal is the easy part. The cold-turkey alcoholic shaking with
delirium tremens might not agree, but only after the body detox-
ifies does the real challenge begin: staying clean. Ex-addicts with
the strongest resolve—and plenty of external motivation in the
form of frayed relationships, probationary jobs, or incipient lung
cancer—struggle to resist cravings and are susceptible to relapse
even years after their last dose (Helmuth, 2001).”
Quitting a drug habit is not easy to accomplish and the jour-
ney to a drug-free life is nothing but an endless personal combat
to resist temptations, even long after detoxification. The inabil-
ity to control drug taking is thought to be a complex disease of
the brain that strikes the most vulnerable individuals and wors-
ens with recurring drug intoxication. The use of psychoactive
substances causes significant health and social problems for the
people who use them, and also for their relatives. The World
Health Organization (WHO) recently estimated that over one bil-
lion people were tobacco users and that alcohol disorders affected
about 80 million people (WHO, 2009). In an initial estimate of
factors responsible for the global burden of disease, tobacco, alco-
hol and illicit drugs contributed together to 12.6% of all deaths
worldwide (up to 19.6% in high income countries) in the year
2000. Tobacco use and alcohol consumption are ranked the sec-
ond and the eighth leading risk factors of death, respectively,
responsible for 5.1 and 2.3 millions of death worldwide each year.
In the U.S., illegal drug use contributes to 17,000 deaths every
year, while over 400,000 people die from tobacco-related disease,
and 85,000 deaths are attributable to the consequences of alcohol
consumption, including alcohol-related illnesses and accidents
(Mokdad et al., 2004). Illicit drug use results in the heaviest bur-
den of mortality in the early years, whereas alcohol and tobacco
use tend to take their toll much later in life, (for alcohol mostly
before the age of 60, and for smoking mostly after the age of
60). Mortality statistics, however, only partially depict the pic-
ture; the frightening truth is that alcohol, tobacco and illicit drug
use accounts for 19.2% of all disability-adjusted life years (DALY)
in high-income countries (WHO, 2009). The DALY accounts for
the burden of chronic illness on the quality of life as well as on
the length of life. It thus extends the concept of potential years
of life lost due to premature death to include equivalent years of
“healthy” life lost by virtue of being in states of poor health or
disability (WHO, 2009). In short, tobacco use and alcohol con-
sumption were ranked the first and the second leading risk factor
causes of DALYs, accountable, respectively for 13 and 8 millions
of DALYs in high-income countries. Besides this unacceptable
human cost, it has been recently reported that addictive disor-
ders cost Europe C65.7 billion (Smith, 2011). It is also estimated
that over 11% of US federal and state government budgets ($374
billion in 2005) are allocated to the consequences of tobacco,
alcohol, and other substance use, abuse, and dependence. Finally,
without alleviating their negative impact on health, it is impor-
tant to note that WHO estimated that only 0.7% of the global
burden of disease in 2004 was due to cocaine and opioid use, with
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the social cost of illicit substance use being approximatively 2%
of Gross Domestic Product in those countries for which it has
been measured. In brief, the treatment of drug addiction should
be a priority in public health policy, and remained a challenge for
both fundamental and clinical investigations.
In this context, there is a general consensus acknowledging
that the reinforcing properties of drugs of abuse arise, at least
in part, from a potentiation of dopaminergic neurotransmission
within the mesocorticolimbic circuit. However, in the search for
effective treatments alleviating signs of drug addiction, this sys-
tem still is the subject of pre-clinical drug development studies
but the results have been rather inconclusive or are still pend-
ing. Meanwhile, emerging data suggests that neurotransmitters
other than dopaminemay also play important roles in themotiva-
tional properties of drugs (Boutrel, 2008). The aim of this review
is to highlight some of the recent evidence demonstrating an
important role for the hypocretin (orexin) neuropeptide system
in regulating the reinforcing properties of most of the categories
of drugs of abuse.
THE HYPOCRETIN/OREXIN SYSTEM IN BRIEF
The hypocretins (Hcrt, also known as orexins) are two neu-
ropeptides, hypocretin-1/orexin-A, and hypocretin-2/orexin-B,
derived from the same precursor gene produced in a few thou-
sand neurons localized in the perifornical area (PFA) of the
lateral hypothalamus (LH) (De Lecea et al., 1998; Sakurai et al.,
1998). Hypocretin-containing neurons arise in the LH area and
project widely in the brain with a dense innervation of anatomical
sites involved in regulating arousal, motivation and stress states,
where the released peptides bind to two G-coupled receptors,
Hypocretin receptor 1 (Hcrtr-1) and Hcrtr-2. Their interaction
with autonomic, neuroendocrine and neuroregulatory systems
strongly suggests that they act as neuromodulators in a wide
variety of neural circuits (Tsujino and Sakurai, 2009). In com-
plement of a wide innervation of various neural circuits, the
hypocretinergic system projects to all the major components of
the extended amygdala (Schmitt et al., 2012), a brain region
known to connect the basal forebrain to the classical reward sys-
tems of the LH via the medial forebrain bundle reward system.
Hence, the hypocretinergic system fulfills both neuroanatomi-
cal and functional criteria to modulate critical connections that
regulate both positive- and negative-reinforcing properties of
drugs of abuse. However, the first compelling evidence actually
established a fundamental role of the Hcrt in the regulation of
arousal. Two outstanding studies unveiled the etiology of nar-
colepsy by linking the Hcrt system to this sleep disease using
animal models (Chemelli et al., 1999; Lin et al., 1999). Further
observations later established that human narcoleptic patients
exhibited reduced levels of Hcrt-1 peptides in the cerebrospinal
fluid and reduced numbers of Hcrt neurons (Nishino et al., 2000;
Peyron et al., 2000; Thannickal et al., 2000). Nowadays, nar-
colepsy is still considered to be critically linked to ongoing loss
of Hcrt neurons. In the current models, Hcrt stabilizes the fir-
ing of brainstem neurons that promote wakefulness and Rapid
Eye Movement (REM) sleep. The Hcrt system is also thought to
exert a strong and direct excitatory effect on cholinergic neu-
rons in the basal forebrain that contributes to cortical arousal
(Tsujino and Sakurai, 2009). In conclusion, the Hcrt system may
be considered as a key regulator that integrates sensory inputs and
orchestrates normal wakefulness and metabolic health (Sutcliffe
and De Lecea, 2002; Adamantidis et al., 2007; Adamantidis and
De Lecea, 2008; Schone and Burdakov, 2012). Noteworthy, a past
conjecture suggested a dichotomy of reward and arousal (Harris
and Aston-Jones, 2006), with a functional heterogeneity among
Hcrt neurons (those in the LH regulating reward processes while
those in the PFA and DMH mostly involved in the regulation of
arousal and stress responses), and a functional dichotomy among
Hcrt receptor signaling (Hcrtr-1 modulating reward seeking and
Hcrtr-2 involved in arousal maintenance) (Gotter et al., 2012).
In this regards, a recent study using functional magnetic reso-
nance imaging reported that Hcrt receptor 1 in the striatum may
specifically regulate reward seeking behaviors while Hcrt recep-
tor 2 signaling in the cortex may preferentially modulate arousal
(Gozzi et al., 2011). However, all compounds that have entered
clinical development for the treatment of insomnia target both
receptors, and it is important to note that, if disruption of the
Hcrt transmission may cause destabilization of the boundaries
between sleep states, some serious concerns may be raised regard-
ing the use of anti-Hcrt medications for alleviating signs of drug
dependence.
EVIDENCE FOR A ROLE OF THE HYPOCRETIN/OREXIN
SYSTEM IN DRUG REWARD
The diminished signs of precipitated opiate withdrawal displayed
by Hcrt knockout mice were the first evidence linking the Hcrt
system to drug addiction (Georgescu et al., 2003). This observa-
tion was confirmed a couple of years later with the demonstration
that activation of LH Hcrt neurons was sufficient to reinstate
an extinguished preference for an environment previously paired
with morphine reward in rats (Harris et al., 2005). The involve-
ment of the Hcrt system in the regulation of heroin intake has
been recently reported (Smith and Aston-Jones, 2012), thus con-
firming the initial assumptions suggesting a key role for the Hcrt
in mediating opiate reinforcement and withdrawal (Georgescu
et al., 2003; Narita et al., 2006; Sharf et al., 2008) (see Table 1).
Interestingly, Hcrt transmission also was shown to play an
important role in regulating alcohol and nicotine seeking behav-
iors. It has been reported that the Hcrtr-1 antagonist SB334867
decreased both alcohol and nicotine self-administration behav-
iors in rats (Lawrence et al., 2006; Hollander et al., 2008; Richards
et al., 2008; Moorman and Aston-Jones, 2009; Lesage et al.,
2010; Jupp et al., 2011a,b; Voorhees and Cunningham, 2011),
and that, conversely, administration of Hcrt directly into the
paraventricular nucleus or in the LH increased ethanol-drinking
without affecting food and water intake (Schneider et al., 2007).
Strikingly, activation of Hcrt neurons also was shown to rein-
state both extinguished alcohol and nicotine seeking (Hamlin
et al., 2007; Dayas et al., 2008; Plaza-Zabala et al., 2013) and
Hcrt signaling was claimed to trigger nicotine withdrawal as well
(Plaza-Zabala et al., 2012). These preclinical observations were
recently confirmed. Indeed, the Hcrt system has been involved in
the affective dysregulation observed in alcohol dependent patients
during alcohol withdrawal (Bayerlein et al., 2011; Von Der Goltz
et al., 2011), in abstinent smokers during nicotine withdrawal
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(Von Der Goltz et al., 2010) and in cannabis abusers (Rotter et al.,
2012).
The respective roles of Hcrtr-1 and Hcrtr-2 remain controver-
sial though. A recent report claimed the effectiveness of the Hcrtr-
2 antagonist JNJ-10397049 in reducing the reinforcing effects
of ethanol, in particular in dose-dependently decreasing ethanol
self-administration without affecting saccharine consumption in
rats (Shoblock et al., 2011). Unexpectedly, the latter study report-
ing that treatment with JNJ-10397049 (10mg/kg, sc) attenuated
the acquisition, expression, and reinstatement of ethanol con-
ditioned place preference and ethanol-induced hyperactivity in
mice, also claimed that the Hcrtr-1 antagonist SB-408124 (3,
10, and 30mg/kg, sc) did not have any effect in these proce-
dures (Shoblock et al., 2011), whereas the studies investigating
the effect of SB 334867 all converged in supporting that Hcrt-1
receptor antagonism decreases ethanol reward. A large consen-
sus remained, however, on the role of both Hcrt receptors in
preventing cue-induced reinstatement of previously extinguished
alcohol-drinking behavior (Lawrence et al., 2006; Shoblock et al.,
2011; Kim et al., 2012; Martin-Fardon and Weiss, 2012) (see
Table 1).
With regards to cocaine, it has been established that daily
pretreatment with the Hcrtr-1 antagonist SB-334867 prevented
cocaine sensitization (Borgland et al., 2006) but did not block
daily cocaine intake in a self-administration procedure (Smith
et al., 2009). In contrast, a single injection of the Hcrtr-1 antago-
nist SB334867 was shown to prevent both Hcrt-, footshock-, and
cue-induced reinstatement of a previously extinguished cocaine
seeking behavior without however reducing cocaine consump-
tion in a fixed ratio schedule of reinforcement (Boutrel et al.,
2005; Smith et al., 2009; Wang et al., 2009; Zhou et al., 2012).
Hcrt transmission may therefore selectively regulate “relapse”
like behaviors in abstinent rats, but may not play any critical
role in the reinforcing effects of the drug that maintain ongoing
drug-taking behavior (see Table 1).
This assumption remains debatable though, since opposite
observations were reported in rats trained to self-administer
cocaine using a progressive ratio schedule of reinforcement, a
procedure during which the number of lever presses required to
earn one reward increases gradually within the session. Indeed,
two studies reported that the final ratio (i.e., number of infu-
sions) obtained by rats before termination of the session remained
unchanged after infusion of the peptide or the receptor antago-
nist (Boutrel et al., 2005; Wang et al., 2009), whereas two other
studies claimed that blockade of Hcrtr-1 with SB-334867 reduced
the performance to self-administer cocaine in rats (Borgland
et al., 2009; Espana et al., 2010). A striking observation, though,
is that very low doses of SB-334867 (1–4mg/kg) were shown
to dose-dependently decrease cocaine self-administration in rats
trained on a fixed ratio 5 schedule of reinforcement (FR5). In
line with this observation, it has also been demonstrated that
Hcrtr-1 antagonism dose-dependently attenuated the stimulatory
effects of cocaine on brain reward systems [as measured by rever-
sal of cocaine-induced lowering of intracranial self-stimulation
(ICSS) thresholds]. Ultimately, it was established that Hcrtr-1
knockout mice (also trained on a FR5) self-administered far
less cocaine than wildtype mice across the entire dose-response
function (Hollander et al., 2012). Thus, a plausible explana-
tion is that Hcrt transmission may be necessary to maintain
cocaine-taking behavior when high levels of effort are required
to obtain the drug, but not when the drug is readily available
(Kenny, 2011).
THE HYPOCRETIN/OREXIN SYSTEM AT THE INTERFACE OF
BRAIN REWARD AND BRAIN STRESS PATHWAYS
Concordant observations point to a role of Hcrt-1 in driv-
ing drug seeking, in particular cocaine, through activation of
the mesolimbic dopamine system. Hcrt-1 peptide has been
shown to be critically involved in cocaine sensitization through
the recruitment of N-Methyl-D-Aspartate (NMDA) receptors
in the ventral tegmental area (VTA) (Borgland et al., 2006).
Conversely, cocaine administration was recently reported to
induce long-lasting, experience-dependent potentiation of gluta-
matergic synapses on hypocretin neurons in mice (Yeoh et al.,
2012; Rao et al., 2013). Hcrt-1 peptide administered into the
VTA was claimed to enhance dopamine responses to cocaine
and promote cocaine self-administration (Espana et al., 2011)
whereas administration of the Hcrtr-1 antagonist SB 334867
attenuated cocaine-induced enhancement of dopamine signaling
(Espana et al., 2010; Calipari and Espana, 2012). Bath applica-
tion of Hcrt-1 was shown to promote local dopamine release
in nucleus accumbens shell slices (Patyal et al., 2012), which is
in line with other reports claiming that Hcrt receptor antag-
onism reduced amphetamine-evoked dopamine outflow in the
shell of the nucleus accumbens and decreased the expression of
both cocaine and amphetamine conditioned reward and sensiti-
zation (Quarta et al., 2010; Winrow et al., 2010; Hutcheson et al.,
2011).
Though, the elevated ICSS thresholds, observed after Hcrt-
1 infusion into the lateral ventricle, rather suggest a decrease
in excitability of brain reward systems (Boutrel et al., 2005).
Indeed, such an elevation of ICSS thresholds does not match with
the cocaine-induced lowering of ICSS thresholds that is consid-
ered to reflect an increased sensitivity that underlies or, at least,
contributes to the positive affective state associated with drug
consumption. In contrast, this long-lasting reward deficit is simi-
lar to that observed after intracerebroventricular (i.c.v) infusion
of corticotropin-releasing factor (CRF) (Macey et al., 2000) or
after drug withdrawal (Markou and Koob, 1991). Hence, this
observation provides strong evidence suggesting that Hcrt-1 rein-
states cocaine seeking by mechanisms different from increased
dopamine release. In line with this observation, recent evidence
suggests that intra-VTA or i.c.v administration of Hcrt-1 exerts its
threshold-increasing effect via subsequent activation of the CRF
system (Hata et al., 2011).
HYPOCRETIN AND THE URGE FOR REWARD SEEKING: AN
ALLOSTATIC ADAPTATION IN BASIC NEEDS
As mentioned above, a large body of evidence demonstrates
the implication of the Hcrt system in many different classes
of drug reward, including cocaine, amphetamine, morphine,
heroin, nicotine, and ethanol. Though, blockade of Hcrtr-1 does
not evidently reduce psychostimulant consumption, whereas it
quite clearly decreases both nicotine and alcohol intake in rats.
Frontiers in Behavioral Neuroscience www.frontiersin.org June 2013 | Volume 7 | Article 59 | 5
Boutrel et al. The hypocretins and the reward function
Importantly, there is a consensus on the role of the Hcrt system
in conditioned responding for drug-associated stimuli (context or
cues), which means Hcrt may be critically implicated in addiction
disease, most likely in stress- and stimulus-induced drug relapses
(Boutrel and De Lecea, 2008).
However, a key question remains unanswered: how a system,
that would be normally involved in the regulation of hyper-
aroused states in accordance with the elaboration of goal-oriented
behaviors, may promote a pathological state that elicits com-
pulsive craving and relapse to drug seeking after a period of
protracted abstinence.
A recent report suggested that, in contrast to chronic calorie
restriction that results in depression- and anxiety-like behav-
iors in rats (Jahng et al., 2007), short-term calorie restriction
would promote increased arousal, increased locomotor activity
and decreased anxiety-like behaviors that could be attributed
to the activation of the Hcrt system. This antidepressant-like
response would be lost after chronic calorie restriction due
to a downregulated expression of prepro-Hcrt mRNA in the
LH (Lutter et al., 2008). Thus, in healthy physiological condi-
tions, the Hcrt system may contribute to a resilient-like state
by reducing depression-like symptoms induced by short-term
calorie restriction, whereas a compromised Hcrt system upon
chronic calorie restriction may contribute to worsen signs of
anxiety and depression (Rotter et al., 2011). Our idea is that
a similar adaptation may occur during chronic drug consump-
tion (and the concomitant recurring drug withdrawals). Indeed,
it is well accepted that Hcrt elicits appropriate levels of alert-
ness to engage exploratory behaviors and strengthen motivation
for food seeking depending on physiological needs (hunger,
thirst). Similarly, at cessation of drug consumption, the Hcrt
system may act as an alarm signal that would prepare the
organism for withdrawal and face the consequences on energy
and fluid homoeostasis (such as starvation activating the Hcrt
and eliciting food seeking to prevent caloric restriction). This
assumption is in line with the diminished signs of precipi-
tated opiate withdrawal displayed by both mutant mice deficient
in Hcrt (Georgescu et al., 2003) and C57BL/6J mice treated
with a Hcrtr-1 antagonist (Sharf et al., 2008). We thus con-
sider that chronic drug intoxication may induce changes in basic
needs priorities, and that the Hcrt may contribute (as a means
to maintain stability of the internal milieu in case of depen-
dence) to a particularly vulnerable state of the brain that may
trigger the urge for drug seeking and drug taking, even long
after last consumption and withdrawal (Boutrel et al., 2010). A
new role would be assigned to the Hcrt system, no longer for
fine tuning arousal and goal-directed behaviors in response to
metabolic needs, but for eliciting the hyperaroused and moti-
vated state, if not anxious-like state (Plaza-Zabala et al., 2010),
required for optimizing drug seeking, in other words drug craving
(Martin-Fardon and Boutrel, 2012).
Since Hcrt fibers have been shown to innervate both the NAcc
(Baldo et al., 2003) and the insula (Hollander et al., 2008), it is
tempting to speculate that Hcrt may contribute to define behav-
ioral strategies by optimizing the processing of environmental
signals in attention-demanding tasks with regard to past expe-
riences. Hence, the Hcrt system may enhance cognitive arousal
and attention for improving prediction making, and drive sus-
tained attention for achieving the goal-oriented behavior what-
ever the context is: reward seeking or punishment avoidance
(Berridge et al., 2010). In line with this interpretation, a recent
study established that cues previously paired with cocaine con-
sumption elicited a significant increase in cFos-positive Hcrt
neurons compared to cues previously paired with sweetened con-
densed milk. Further, following the extinction, the number of
Fos-positive Hcrt cells was decreased in cocaine rats compared
to drug naïve ones and those exposed to the sweetened con-
densed milk, suggesting a decreased activity in Hcrt neurons of
rats with a history of drug abuse. Strikingly, the Hcrtr-1 antago-
nist SB334867 was shown to reduce cue-induced cocaine seeking
at lower doses (starting at 3mg/kg) than those used for preventing
cue-induced sweetened condensed milk seeking (Martin-Fardon
et al., 2010). Again, chronic drug intoxicationmay induce changes
in basic needs priorities, and the Hcrt system may be part of a
common mechanism for adapting and/or ranking priorities and
eliciting appropriate levels of alertness to drive attention pro-
cesses and trigger goal-directed behaviors according to these new
priorities.
POTENTIAL CONSEQUENCES OF A PHARMACOLOGICAL
DISRUPTION OF Hcrt TRANSMISSION
With the accumulation of preclinical evidence demonstrating
a role for Hcrt in the maintenance of arousal, several phar-
maceutical companies have developed Hcrt receptor antagonists
for the treatment of insomnia. SB-334867 was the first Hcrtr-
1 antagonist developed by GlaxoSmithKline (GSK) in the late
nineties and remains to date the most studied Hcrtr-1 antag-
onist. Several other Hcrtr-1 and Hcrtr-2 antagonists, consen-
sually called SORA for Single Orexin Receptor Antagonists, as
well as ligands with similar affinity for both receptors, also
called DORA for Dual Orexin Receptor Antagonists, have been
developed then. Exhaustive reviews covering patent literature
published between 1999 and 2009 have been recently issued
(Coleman and Renger, 2010; Scammell and Winrow, 2011). But
these technical reports focused mainly on the chemical prop-
erties of these compounds. Further therapeutic opportunities
offered by Hcrt ligands have been recently examined, however
these reviews of the literature cover essentially the pharmacol-
ogy of sleep and arousal (Coleman and Renger, 2010; Scammell
and Winrow, 2011). Very few compounds have entered clini-
cal development. Actelion, in partnership with GSK, has been
conducting Phase III studies with the DORA almorexant for
the treatment of insomnia, and Merck reported that the DORA
MK-4305 (Suvorexant) entered into Phase III development for
treating insomnia and claimed encouraging preliminary studies
with the DORA MK-6096 (DORA-22) (Coleman et al., 2012;
Herring et al., 2012; Willyard, 2012; Mignot, 2013; Sun et al.,
2013; Uslaner et al., 2013). Nevertheless, it has not been yet
reported any clinical investigations with one of these compounds
for treating drug addiction. Thus far, little is known on the puta-
tive adverse effects of Hcrt receptor antagonists. Nevertheless,
a rapid review of the available evidence allows us to raise a
few concerns about the effects of a pharmacological disrup-
tion of the Hcrt transmission (Scammell and Winrow, 2011).
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In addition to the prominent role of the Hcrt system in arousal
stability, Hcrt have been suggested to play a key role in driv-
ing arousal and goal-oriented behaviors (Boutrel et al., 2010).
Briefly, compelling evidence has established a role for the Hcrt in
enhancing cortical arousal and attention, particularly with regard
to limbic and visceral states (Huang et al., 2006). In particular,
Hcrt cells were shown to discharge with maximal activity during
exploratory behavior, which can be considered as sustained atten-
tion or alertness (Mileykovskiy et al., 2005). Confirming this idea,
systemic or intracerebral administration of the Hcrtr-1 antagonist
SB 334867 has been shown to disrupt attention in rats (Boschen
et al., 2009). In line with these preclinical reports, recent clinical
observation reported that narcoleptic patients exhibited attention
deficits that cannot be attributed to sleepiness only (Rieger et al.,
2003). Disruption of Hcrt signaling might therefore constitute a
risk for developing attention deficits and quite serious long-term
debilitating effects.
Further, Hcrt neurons are sensitive to glucose, leptin, triglyc-
erides, and carbon dioxide concentrations, and have long been
considered to maintain physiological levels of caloric intake.
Nevertheless, recent evidence suggests that Hcrt do not seem
to be critical players in food intake behaviors, but rather adapt
arousal and motivation levels to allow feeding and drinking
behaviors (Tsujino and Sakurai, 2009). Depending on physio-
logical needs (hunger, thirst), Hcrt elicits appropriate level of
arousal to engage exploratory and goal-oriented behaviors. This
can ultimately strengthen motivation for palatable food and liq-
uids (Kunii et al., 1999; Thorpe et al., 2005; Borgland et al., 2009)
or lead to the reinstatement of a previously extinguished food
seeking behavior in an operant conditioning paradigm (Boutrel
et al., 2005; Nair et al., 2008). Consistent with this possibility,
the inhibitory effects of SB-334867 on consumption of a palat-
able reinforcer (high-fat chocolate food) were recently suggested
to be dependent upon the level of effort necessary to obtain
the reinforcer (Borgland et al., 2009). Indeed, intra-LH Hcrt-
1 had the greatest effects at higher effort-requiring schedules,
whereas Hcrtr-1 signaling appeared to have little involvement
in responding for high fat or sucrose pellets in low effort situ-
ations (Thorpe et al., 2005; Borgland et al., 2009). Nonetheless,
recent findings using a pharmacological disruption of Hcrt trans-
mission have shown that Hcrtr-1 plays an important role in the
motivation to respond for both food (Sharf et al., 2010) and
sweetened taste (Cason and Aston-Jones, 2013a,b), confirming
that Hcrt neurotransmission is as critical for modulating the
reinforcing and conditioned rewarding effects of non-drug rein-
forcers as it is for drugs of abuse. Thus, disrupting the Hcrt
system may represent serious concerns with regards to appetite
regulation.
Besides, it seems that the Hcrt do not drive alertness elicited by
physiological needs only, but in response to psychological needs
as well. Indeed, concordant evidence has recently suggested that
Hcrt may potentiate male sexual behavior in rats (Gulia et al.,
2003; Muschamp et al., 2007; Bai et al., 2009; Di Sebastiano
et al., 2010, 2011; Di Sebastiano and Coolen, 2012) in a way that
facilitates the energized pursuit of sexual engagement. Strikingly,
higher Hcrt-1 content was found in mid brain, medulla and
thalamus harvested at late proestrus relative to all other stages of
the sex cycle in female rats (Russell et al., 2001). These observa-
tions are considered to reflect greater release of Hcrt-1 into nerve
endings in brain areas implicated in sex cycle-specific behaviors,
such as lordosis and sexual receptivity in female rats (Russell et al.,
2001). Therefore, Hcrt may promote sexual arousal in both male
and female rats. Interestingly, the main reinforcing behavior in
females is considered to be maternal care. Not surprisingly, Hcrt-
1 modulates maternal behavior in mice (D’Anna and Gammie,
2006). Hence, not only does Hcrt drive appropriate levels of alert-
ness in response to thirst and hunger, but also it triggers sexual
arousal and sustained maternal care. It is then tempting to sug-
gest a role for Hcrt in adapting/strengthening coping strategies in
animals facing desire and needs. Again, this observationmay raise
quite a few concerns with regards to a long-term disruption of the
Hcrt system.
CONCLUSION
The Hcrt system controls sleep and wakefulness through multi-
ple interactions with brain structures involved in the regulation
of emotion, reward, stress, and energy homeostasis. A consen-
sus has emerged on the role of Hcrt in eliciting appropriate
levels of arousal to engage exploratory and goal-oriented behav-
iors depending on physiological needs. Our hypothesis is that
chronic drug intoxication may compromise these basic needs
priorities, and the Hcrt system may become “hijacked” and con-
sequently, may drive drug-oriented behaviors according to these
new priorities. This assumption is supported by a large body
of evidence demonstrating a role for the Hcrt system in drug
reward, particularly in “relapse-like” behaviors in abstinent rats.
Further, converging data now suggest a role for Hcrt in the
affective dysregulation observed in dependent patients during
alcohol and nicotine withdrawal. Still, it remains unclear whether
Hcrt antagonism may offer a clinical opportunity for reduc-
ing alcohol and nicotine (and possibly opiate) consumption in
dependent patients. Unfortunately, it appears quite clear that
disrupting the Hcrt system most likely will not reduce cocaine
or amphetamine intake. A large consensus remains though on
the possibility to treat dependent patients with Hcrt receptor
blockers for alleviating symptoms of drug dependence, notably
the urge for drug seeking during protracted abstinence from
most major drugs of abuse. As reviewed above, the beneficial
effects of such a medication may be limited by some serious
side effects among which sleepiness, decreased appetite, attention
deficits, and reduced libido. In conclusion, there is consider-
able evidence that the Hcrt system is key to many aspects of
reward seeking behaviors and, thus, could be a useful target for
controlling relapse for drugs of abuse. However, the fundamen-
tal role of these systems in more basic aspects of homeostasis
and non-drug reinforcement need to be carefully considered in
order to ensure that unintentional adverse consequences are not
presented.
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